Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
The FDA has approved Mounjaro (tirzepatide) to reduce the risk of major cardiovascular events — including heart attack and stroke — in adults with type 2 diabetes at high cardiovascular risk. The approval is backed by the SURPASS-CVOT trial, which showed Mounjaro cut major adverse CV events by 8% more than rival drug Trulicity. It's the latest expansion for Eli Lilly's blockbuster GLP-1/GIP drug.
The FDA has approved Mounjaro (tirzepatide) for a new indication: reducing the risk of major adverse cardiovascular events — including CV death, nonfatal heart attack, and nonfatal stroke — in adults with type 2 diabetes who are at high cardiovascular risk. Eli Lilly's dual GLP-1/GIP receptor agonist was already approved for blood sugar control in patients aged 10 and older, and this new label expansion marks a significant step in positioning the drug as a comprehensive metabolic and heart health treatment.
The approval is grounded in data from the SURPASS-CVOT trial, a large head-to-head study comparing tirzepatide against dulaglutide (Trulicity), a GLP-1 drug with established cardiovascular benefits. Tirzepatide proved noninferior to dulaglutide and edged it out with an 8% lower risk of major adverse CV events. Safety results were consistent with prior studies, with side effects mostly gastrointestinal, mild to moderate, and concentrated during dose escalation.
By the Numbers:
Why it matters: This approval gives clinicians a single agent that addresses both glycemic control and cardiovascular risk — two of the biggest concerns in type 2 diabetes management. It also intensifies the competitive race between Eli Lilly and Novo Nordisk, whose GLP-1 drugs Wegovy and Rybelsus have already secured similar heart-protective indications.
